Warner Chilcott claimed that LO Loestrin FE offers women the lowest dosage of estrogen (10mcg) of any oral contraceptive currently available in the US market.
LO Loestrin FE is expected to be launched by Warner Chilcott in early 2011.
Warner Chilcott president and CEO Roger Boissonneault said that they were excited about the approval of LO Loestrin FE, which complements their women’s healthcare franchise and expands the product offerings in their branded oral contraceptive portfolio.
Warner Chilcott is a specialty pharmaceutical company currently focused on the gastroenterology, women’s healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.